{"id":"cefepime-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Phlebitis at injection site"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cefepime works by disrupting the cross-linking of peptidoglycan in the bacterial cell wall, leading to cell wall instability and bacterial death. It has broad-spectrum activity against both gram-positive and gram-negative bacteria, including some Pseudomonas aeruginosa strains. As a fourth-generation cephalosporin, it has enhanced activity against gram-negative organisms compared to earlier generations.","oneSentence":"Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:22.405Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections including pneumonia, febrile neutropenia, urinary tract infections, and intra-abdominal infections"},{"name":"Empiric therapy for hospitalized patients with suspected gram-negative or gram-positive bacterial infections"}]},"trialDetails":[{"nctId":"NCT06748144","phase":"PHASE2, PHASE3","title":"IO Vancomycin Spine","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-05","conditions":"Lumbar Fusion Surgery","enrollment":30},{"nctId":"NCT04948463","phase":"PHASE4","title":"Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2021-11-15","conditions":"Febrile Neutropenia","enrollment":55},{"nctId":"NCT07283068","phase":"NA","title":"IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-02-15","conditions":"Revision Total Knee Arthroplasty","enrollment":40},{"nctId":"NCT05831774","phase":"PHASE4","title":"IO Vancomycin in TSA","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-06-01","conditions":"Shoulder Injuries","enrollment":33},{"nctId":"NCT06384651","phase":"PHASE4","title":"Intraosseous vs. Intravenous Vancomycin Administration in Total Ankle Arthroplasty","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-12-03","conditions":"Infections, Ankle Arthritis","enrollment":40},{"nctId":"NCT05705843","phase":"PHASE4","title":"IO vs IV Vancomycin in Tourniquetless TKA","status":"UNKNOWN","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-01-25","conditions":"Infection, Surgical Site","enrollment":40},{"nctId":"NCT05588531","phase":"PHASE1","title":"Study on Tolerance, Pharmacokinetics and Drug Interaction of YK-1169 in Healthy Volunteers","status":"COMPLETED","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2021-12-20","conditions":"Pharmacokinetics","enrollment":66},{"nctId":"NCT04187755","phase":"PHASE4","title":"Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2019-03-01","conditions":"Neutropenia, Febrile, Leukemia, Pediatric Cancer","enrollment":72},{"nctId":"NCT02302092","phase":"PHASE3","title":"An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections","status":"TERMINATED","sponsor":"Takeda","startDate":"2015-12-01","conditions":"Urinary Tract Infection","enrollment":13}],"_emaApprovals":[],"_faersSignals":[{"count":17,"reaction":"DEATH"},{"count":3,"reaction":"PULMONARY HAEMORRHAGE"},{"count":3,"reaction":"RENAL FAILURE ACUTE"},{"count":2,"reaction":"RESPIRATORY FAILURE"},{"count":1,"reaction":"ACUTE FEBRILE NEUTROPHILIC DERMATOSIS"},{"count":1,"reaction":"ACUTE RESPIRATORY DISTRESS SYNDROME"},{"count":1,"reaction":"ALOPECIA"},{"count":1,"reaction":"CARDIAC FAILURE ACUTE"},{"count":1,"reaction":"CHRONIC GRAFT VERSUS HOST DISEASE"},{"count":1,"reaction":"CONFUSIONAL STATE"}],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cefepime Injection","genericName":"Cefepime Injection","companyName":"Murdoch Childrens Research Institute","companyId":"murdoch-childrens-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections including pneumonia, febrile neutropenia, urinary tract infections, and intra-abdominal infections, Empiric therapy for hospitalized patients with suspected gram-negative or gram-positive bacterial infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}